Accelerated Treatment of Endocarditis Comparing Shorter and Standard Antibiotic Durations

What this Trial Is About

Researchers are evaluating a shorter antibiotic treatment for patients with left-sided infectious endocarditis caused by Streptococci, Enterococcus faecalis, or Staphylococcus aureus. The study aims to assess whether reducing the treatment duration, based on individual patient response and clinical data, is as safe and effective as the standard longer treatment. This approach may reduce hospital stays and related risks such as mental strain and loss of function. Participants are randomly assigned to receive either accelerated antibiotic treatment or the standard length of treatment. The accelerated group receives shorter treatment durations tailored to the type of bacteria and disease complexity, ranging from 2 to 4 weeks, with adjustments after cardiac surgery. The standard group follows usual treatment durations of 4 to 6 weeks depending on bacterial type and disease status. This open-label study includes approximately 475 patients. During the study, researchers monitor safety outcomes such as mortality, embolic events, and unplanned heart surgery up to 6 months after randomization. They also assess efficacy by measuring days alive without antibiotic treatment and track secondary outcomes including hospital stay length, treatment costs, catheter complications, and recurrence of infection. Participants undergo regular clinical evaluations, laboratory tests, and follow-up visits to collect these data throughout the study period.

Accelerated Treatment of Endocarditis